EGFR-family expression and implications for targeted radionuclide therapy

Targeted Radionuclide Tumor Therapy: Biological Aspects

Volumn , Issue , 2008, Pages 25-58

  Carlsson, Jörgen ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62449280265     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8696-0_3     Document Type: Chapter

References (188)

1. McGill MA, McGlade CJ (2004) Cellular signaling. In: The Basic Science of Oncology (editors: Tannock IF, Hill RP, Bristow RC and Harrington L). McGraw-Hill Medical Publishing Division, New York (ISBN-13:978-0-07-138774-3), Chapter 8, pp142-166
2. Pecorino L (2005) Molecular Biology of Cancer. Mechanisms, Targets and Therapeutics. Oxford University Press, Oxford (ISBN 0-19-926472-4)
3. Carlsson J, Forssell AE, Hietala SO, Stigbrand T, Tennvall J (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66:107-17
4. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147-57. Review
5. De Nardo SJ, De Nardo GL (2006) Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 66(Suppl 2):S89-95. Review
6. Goldenberg DM, Sharkey RM (2006) Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50(4):248-64. Review
7. Witzig TE (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 19(4):655-68. Review
8. Wong JY (2006) Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys 66(Suppl 2):S74-82. Review
9. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505-16
10. Bublil EM, Yarden Y (2007) The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19(2):124-34. Review
11. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341-54.
12. Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12(18):5268-72. Review
13. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-85
14. Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1):4-12. Review
15. Gusterson B, Cowley G, Smith JA, Ozanne B (1984) Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 8:649-58
16. Damjanov I, Mildner B, Knowles BB (1986) Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 55:588-92
17. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A (1990) Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45:457-61
18. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-62
19. Plowman GD, Culouscou JM, Whitney GS (1993) Ligand-specific activation of HER4/p180 erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90(5):1746-50
20. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ (2000) Nuclear expression of the c-erbB 4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60(6):1483-7
21. Ekberg T, Nestor M, Engstrom M, Nordgren H, Wester K, Carlsson J, Anniko M (2005) Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26(5):1177-85
22. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J (2007) EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31:493-9
23. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M, Buchler MW (1999) Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c erbB-3. World J Surg 23:1010-8
24. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4317-23
25. Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H, Moinfar F (2006) Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol 101:18-23
26. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46
27. Gullick WJ (1996) The c-erbB3/HER3 receptor in human cancer. Cancer Surv 27:339-49.
28. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ (1998) Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185(3):236-45
29. Gullick WJ (2003) c-erbB-4/HER4: friend or foe? J Pathol 200:279-81
30. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP (2000) Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6(11):4217-25
31. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290-7
32. Fuchs IB, Siemer I, Buhler H, Schmider A, Henrich W, Lichtenegger W, Schaller G, Kuemmel S (2006) Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer Res 26(6 B):4397-401
33. Bartsch R, Wenzel C, Zielinski CC, Steger GG (2007) HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs 21(2):69-77. Review
34. Moasser MM (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene May 7 [Epub ahead of print]
35. Nahta R, Esteva FJ (2007) Trastuzumab: triumphs and tribulations. Oncogene 26(25):3637-43
36. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90:2344-8
37. Lan KH, Lu CH, Yu D (2005) Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 1059:70-5. Review
38. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269-80. Review
39. Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108:334-41
40. Winter JL, Stackhouse BL, Russell GB, Kute TE (2007) Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med 131(5):767-72
41. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203(4):918-26
42. Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S, Friese K (2004) Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow. Breast Cancer Res Treat 87(1):65-74
43. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J 13(2):122-9
44. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG (2004) Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6(3):R246-51
45. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD (1996) Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56(16):3823-30
46. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW (2007) Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 13(6):1926-35
47. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU, Carlsson J (2007) [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 67(1):326-31
48. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandstrom M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY (2007) Radionuclide therapy of HER2 positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67(6):2773-82
49. Gardmark T, Wester K, De la Torre M, Carlsson J, Malmstrom PU (2005) Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 95(7):982-6
50. Alonzi R, Hoskin P (2005) Novel therapies in bladder cancer. Clin Oncol (R Coll Radiol) 17(7):524-38. Review
51. Adam L, Kassouf W, Dinney CP (2005) Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am 32(2):239-46. Review
52. Baffa R, Letko J, McClung C, Le Noir J, Vecchione A, Gomella LG (2006) Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res 25(2):145-60. Review
53. Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J, Westlin JE, Busch C, Malmstrom PU (1998) Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 76:189-93
54. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU (2002) HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41:282-8
55. Rotterud R, Nesland JM, Berner A, Fossa SD (2005) Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 95(9):1344-50
56. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E (2006) The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 94:1703-9
57. Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang XJ, Pan CX, Zhou H, Montironi R, Cheng L (2007) Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 13(3):953-7
58. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40(1):56-63
59. Wulfing C, von Struensee D, Bierer S, Bogemann M, Hertle L, Eltze E (2005) Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy Aktuelle Urol 36(5):423-9
60. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC (2007) National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25(16):2218-24
61. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE Wood DP Jr, Grignon DJ (2001) Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7(8):2440-7
62. Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers (2005) Cancer Control 12(2):105-10. Review
63. Beaven AW, Goldberg RM (2006) Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. Oncology (Williston Park) 20(5):461-9. Review
64. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL (1992) Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1(1):97-105
65. Porebska I, Harlozinska A, Bojarowski T (2000) Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21(2):105-15
66. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majo J, Benavente S, Armengol M, de Torres I (2005) Grupo Espanol de Investigacion Clinica en Oncologia Radioterapica (GICOR). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74(2):101-8
67. Lee JC, Wang ST, Chow NH, Yang HB (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8):1065-71
68. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE (2004) Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10(9):3069-75
69. Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S, de Torres I (2002) Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54(5):1460-5
70. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg P V, Lenz HJ (2006) Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer 6(3):214-8
71. De Luca A, Pignata S, Casamassimi A, D'Antonio A, Gridelli C, Rossi A, Cremona F, Parisi V, De Matteis A, Normanno N (2000) Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin Cancer Res 6(4):1439-44
72. Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A (2003) Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. Int J Oncol 22(2):425-30
73. Dursun A, Poyraz A, Suer O, Sezer C, Akyol G (2001) Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 7(1):24-7
74. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38(2):96-104
75. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38(17):2258-64
76. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, Dietel M, Petersen I (2002) Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 440(2):187-94
77. Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105(6):796-802
78. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A (2005) Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 27(3):225-8
79. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S, Tahara E (1995) Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 25(6):240-9
80. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS (1991) Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 88(17):7792-6
81. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29(8):771-7
82. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126(4):205-11
83. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1(5):545-50
84. Shah RB, Ghosh D, Elder JT (2006) Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66(13):1437-44
85. Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M (2007) Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncol Rep 18(2):503-11
86. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9(3):1200-10
87. Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M (2005) Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 93(5):964-75
88. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM (2004) Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90(2):449-54
89. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J (2005) Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 205(4):522-9
90. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J (1999) Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 84(4):421-5
91. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, Nogue M, Domenech M, Fabregat X (2004) Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 10(14):4742-5
92. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE (1994) Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86(15):1140-5
93. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D (2001) HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116(2):234-9
94. Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, La Salle JM (2001) Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J 7(5):395-403
95. Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L, Chauveinc L (2004) Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 90(2):443-8
96. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxanebased therapy. J Clin Oncol 25(6):675-81
97. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy naive patients with hormone-refractory prostate cancer. J Clin Oncol 25(3):257-62
98. Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H, Zhang Z (2007) Suppresion of salivary adenoid cystic carcinoma growth and metastases by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer 120:1909-13
99. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH (2004) Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95
100. Solit DB, Rosen N (2007) Targeting HER2 in prostate cancer: where to next? J Clin Oncol 25(3):241-3
101. Schwartz S Jr, Caceres C, Morote J, De Torres I, Rodriguez-Vallejo JM, Gonzalez J, Reventos J (1999) Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. Int J Oncol 14(2):367-71
102. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM (2004) HER2 and COX2 expression in human prostate cancer. Eur J Cancer 40(1):50-5
103. Brys M, Stawinska M, Foksinski M, Barecki A, Zydek C, Miekos E, Krajewska WM (2004) Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Oncol Rep 11(1):219-24
104. Hegeman RB, Liu G, Wilding G, McNeel DG (2004) Newer therapies in advanced prostate cancer. Clin Prostate Cancer 3(3):150-6. Review
105. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113(4):619-28
106. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12(1):123-30
107. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N and Volant A (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93:107-15
108. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118:1173-80
109. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, Franklin W, Said S, Varella-Garcia M (2005) Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111-9
110. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Hofler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59(6):631-4
111. Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE 2nd, D'Amico TA (2001) Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72:859-66
112. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9:6461-8
113. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G (2006) Predictive factors for outcome in a phase II study of Gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612-9
114. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12(14):4283-7
115. Lam KY, Tin L, Ma L (1998) C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 24:431-5
116. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H (2005) Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92:1253-1260
117. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, Bergqvist M (2006) HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 19(4):224-31
118. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20:120-9
119. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M, Sasai K (2003) c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57:1323-7
120. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ (1992) Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7(7):1273-8
121. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H (1994) Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74:795-804
122. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666-72. Review
123. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N (1992) Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 14(1):8-13
124. Xia W, Lau YK, Zhang HZ (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5(12):4164-74
125. Santini J, Formento JL, Francoual M (1991) Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13(2):132-9
126. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J (2001) Activated extracellular signal regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61(17):6500-10
127. Khademi B, Shirazi FM, Vasei M, Doroudchi M, Gandomi B, Modjtahedi H, Pezeshki AM, Ghaderi A (2002) The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184(2):223-30
128. Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R (2004) Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 204(3):317-25
129. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J (2005) Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124(1):71-6
130. Craven JM, Pavelic ZP, Stambrook PJ (1992) Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 12(6 B):2273-6
131. Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G (2000) c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res 20(2 A):997-1004.
132. Khan AJ, King BL, Smith BD, Smith GL, Di Giovanna MP, Carter D, Haffty BG (2002) Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8(2):540-8
133. Schartinger VH, Kacani L, Andrle J, Schwentner I, Wurm M, Obrist P, Oberaigner W, Sprinzl GM (2004) Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 66(1):21-6
134. Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T (1995) Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett 95(1-2):79-83
135. Ocharoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA (2002) The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 38(7):627-40. Review
136. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR (1997) Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 17(6 D):4539-46
137. Bei R, Pompa G, Vitolo D (2001) Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195(3):343-8
138. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624-36
139. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430-46
140. Benjamin R, Capparella J, Brown A (2003) Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 9:82-90
141. Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD (2004) Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 4:1453-71
142. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-70
143. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN (2003) Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63:413-6
144. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12(24):7261-70. Review
145. Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML (1998) Radiotherapy of glioblastoma multiforme: feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 174:629-32
146. Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709-20
147. Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181-93. Review
148. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-96
149. Blomquist E, Carlsson J (1991) Strategy for planned radiotherapy of malignant gliomas. Postoperative treatments with high dose proton irradiation and tumor seeking radionuclides. Int J Radiat Oncol Biol Phys 22:259-63
150. Zalutsky MR (2004) Targeted radiotherapy of brain tumours. Br J Cancer 90:1469-73
151. Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, Levitt R (2003) Role of Her 2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 26(4):332-5
152. Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA, Levitt R (2004) Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 22(4):537-44
153. Epenetos AA, Courtenay-Luck N, Pickering D, Hooker G, Durbin H, Lavender JP, McKenzie CG (1985) Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J (Clin Res Ed) 290:1463-6.
154. Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ (1989) Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636-45
155. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22:225-30
156. Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, Rodeck U (2002) Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25:541-6.
157. Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nister M (2006) Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. J Neurooncol 77(1):33-45. Review
158. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130-40
159. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96
160. Ohman L, Gedda L, Larsson R, Stigbrand T, Wester K, Carlsson J (2002) A new antibody recognising the vIII mutation of human EGFR. Tumor Biol 23(2):61-9
161. Nordberg E, Steffen AC, Persson M, Sundberg AL, Carlsson J, Glimelius B (2005) Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. Eur J Nucl Med Mol Imaging 32(7):771-7
162. Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V, Carlsson J (2006) Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 33(6):631-8
163. Nestor M, Ekberg T, Dring J, van Dongen G, Wester K, Tolmachev V, Anniko M (2007) Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinoma using a single dose radioimmunoassay. Tumour Biol 28(5):253-63
164. Bertram JS (2002) The molecular biology of cancer. Mol Aspects Med 21:167-223
165. Onyango P (2002) Genomics and cancer. Curr Opin Oncol 14:79-85
166. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259-65
167. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, Sugihara K (2000) C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73:17-20
168. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141-6
169. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61:5345-8
170. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-43
171. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X (2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94:2169-73
172. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y (2002) EGFR, c erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur J Surg Oncol 28:383-7
173. Sekido Y, Umemura S, Takekoshi S, Suzuki Y, Tokuda Y, Tajima T, Osamura RY (2003) Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 22(6):1225-32
174. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93(5):552-6
175. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H (2002) Amplification of Her 2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15:116-24
176. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, Negri F, Martella E, Naldi N, Franciosi V, Cascinu S (2003) HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 99(5):310-5
177. Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103(9):1763-9
178. Lopez-Guerrero JA, Llombart-Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, Vazquez-Alvadalejo C, Llombart-Bosch A (2006) HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer 118(7):1743-9
179. Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9(3):1-8
180. Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Freneaux P, Dieras V, Thiery JP, Sastre-Garau X (2007) HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96(4):654-9
181. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67(9):4190-8
182. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28(4):971-9
183. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5):1331-46
184. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22(23):4772-8
185. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF (2005) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 16(9):1503-7
186. Bralet MP, Paule B, Adam R, Guettier C (2005) Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J Clin Oncol 23(24):5844-5
187. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung K Y, Yao D, Paty PB, Gerald W, Chen B (2005) Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18(10):1350-6
188. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2007) Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 97(1):92-7